The IC50 of both JQ1 and birabresib, estimated after 72 h of drug exposure, is generally lower than the IC50 for a panel of lymphoid cell lines, including cell lines derived from c‐MYC‐driven lymphomas such as “double‐hit” and Burkitt's lymphomas,28, 29, 30, 31 suggesting a potent antiproliferative activity of JQ1 and birabresib alone in cases of HHV8‐unrelated effusion large B‐cell lymphoma. Here, MYC is linked to Burkitt lymphoma.